Personalised neoadjuvant therapy planning for adults with high‑risk soft tissue sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi‑centre cohort project collects both retrospective and prospective tumor tissue and clinical data from adults with high‑risk soft tissue sarcomas, including dedifferentiated liposarcoma, leiomyosarcoma, synovial sarcoma, vascular sarcomas and MPNST. Patients are enrolled in two cohorts: those who proceed directly to surgery and those who receive neoadjuvant chemotherapy followed by surgery. Pseudonymised samples and data are shared under HTA‑compliant agreements and analyzed at dedicated translational laboratories to identify biomarkers associated with chemotherapy response. The collaboration across five European sarcoma centres aims to increase sample size and enable comparative, stratified analyses to inform personalised neoadjuvant approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent for the prospective cohort

  * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval.
  * High-risk sarcoma definition:

    * Greater than 5cm or Grade 3
    * Deep anatomic location
  * Have disease amenable to biopsy

    o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study
  * Resectable tumour
  * Measurable disease by RECIST 1.1
  * Aged ≥ 18 years
  * WHO performance status 0-2
  * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy
  * Patients medically fit enough to undergo surgical resection
  * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule
  * Patients may also participate in the STRASS 2 trial

Exclusion Criteria:

-Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI.

* Known additional malignancy that is progressing or requires active treatment
* Metastatic disease not amenable to curative intent local therapy
* Any active uncontrolled medical conditions

Where it's running

• The Royal Marsden Hospital
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Stephanie Elston, MSc
• Email: PANTHRS.Trial@rmh.nhs.uk
• Phone: 02073528171

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dose‑escalated, short‑course proton radiation for inoperable soft tissue sarcoma

  This will try higher-dose, shorter-course proton radiation to see if it controls tumors better in adults with inoperable soft tissue sarcoma.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT07173972

• Moderately Hypofractionated Neoadjuvant Radiotherapy for Soft Tissue Sarcoma of the Limbs or Trunk Wall

  This trial tests whether giving a shorter course of radiotherapy before surgery helps control soft tissue sarcoma in the limbs or trunk without waiting longer.

  Recruiting Phase 2 Centre Oscar Lambret · Lille · NCT07507773

• Three-week preoperative proton versus X-ray radiotherapy for localized soft tissue sarcoma

  This trial tests whether selecting proton rather than standard X‑ray radiotherapy before surgery for adults with localized soft tissue sarcoma can lower long-term radiation side effects without increasing surgical complications.

  Recruiting Phase 2 Oslo University Hospital · Bergen and 3 other locations · NCT07169344

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• AYA Sarcoma Survivors: Personalized Exercise Program Pilot

  This pilot tests a personalized 12-week exercise program for adolescents and young adults with sarcoma to see if a triage tool can connect them with the right rehabilitation and exercise services.

  Recruiting at 3 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07662239

• Fluorescence-guided surgery to optimize sarcoma margins

  This will try using an injected fluorescent dye (ICG) during surgery to see if it reduces positive margins and reoperations for adults having curative surgery for intermediate-to-high grade soft tissue sarcoma of the trunk or limbs.

  Recruiting at 2 sites University of Aarhus · Aarhus N and 1 other locations · NCT07134192

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.